New meningitis vaccine shows promise for toddlers in phase 3 trial

NCT ID NCT03890367

Completed ⭐️ VACCINE ⭐️ Sponsor: Sanofi Pasteur, a Sanofi Company Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 3 trial tested a new vaccine (MenACYW) in 707 healthy toddlers aged 12-23 months. The vaccine aims to protect against four types of meningococcal bacteria that can cause meningitis and sepsis. Researchers compared the new vaccine to two existing vaccines (Nimenrix and NeisVac-C) to see if it works as well or better. The study measured immune responses and safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MenACYW conjugate vaccine (meningococcal vaccine)
What this could lead to: If successful, this could provide a new option to protect toddlers against four types of meningococcal bacteria, potentially offering better or equal protection compared to current vaccines.
What could go wrong: This trial is already completed, so results are known. However, the new vaccine may not prove superior to existing ones, and like all vaccines, it can cause side effects such as injection site reactions or fever.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MENINGOCOCCAL IMMUNISATION (HEALTHY VOLUNTEERS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

meningococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MENINGOCOCCAL IMMUNISATION (HEALTHY VOLUNTEERS)

Contacts and locations

Locations

Investigational Site Number 2080001

Aarhus, 8200, Denmark
Investigational Site Number 2080002

Hvidovre, 2650, Denmark
Investigational Site Number 2080003

Odense, 5000, Denmark
Investigational Site Number 2460001

Tampere, 33100, Finland
Investigational Site Number 2460002

Turku, 20520, Finland
Investigational Site Number 2460003

Pori, 28100, Finland
Investigational Site Number 2460004

Jarvenpaa, 04400, Finland
Investigational Site Number 2460005

Helsinki, 00100, Finland
Investigational Site Number 2460006

Espoo, 02230, Finland
Investigational Site Number 2460007

Oulu, 90220, Finland
Investigational Site Number 2460008

Kokkola, 67100, Finland
Investigational Site Number 2460010

Seinäjoki, 60100, Finland
Investigational Site Number 2760002

Erfurt, 99086, Germany
Investigational Site Number 2760003

Mönchengladbach, 41236, Germany
Investigational Site Number 2760004

Bramsche, 49565, Germany
Investigational Site Number 2760005

Mönchengladbach, 41236, Germany
Investigational Site Number 2760006

Schönau, 83471, Germany
Investigational Site Number 2760007

Hürth, 50354, Germany
Investigational Site Number 2760008

Schwaigern, 74193, Germany
Investigational Site Number 2760009

Schweigen, 76889, Germany
Investigational Site Number 2760010

Tuttlingen, 78532, Germany
Investigational Site Number 2760011

Mannheim, 68161, Germany
Investigational Site Number 2760012

Wolfsburg, 38448, Germany
Investigational Site Number 2760013

Itzehoe, 25524, Germany
Investigational Site Number 2760015

Bönnigheim, 74357, Germany
Investigational Site Number 2760017

Hamburg, 22415, Germany
Investigational Site Number 2760018

Tauberbischofsheim, 97941, Germany
Investigational Site Number 2760019

Bretten, 75015, Germany
Investigational Site Number 2760020

Herxheim, 76863, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.